ARROWHEAD PHARMACEUTICALS INC (ARWR)
Sector: Health Care
2026 Annual Meeting Analysis
ARROWHEAD PHARMACEUTICALS INC · Meeting: March 19, 2026
Directors FOR
7
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
As CEO and founder, Dr. Anzalone has led the company through exceptional 3-year stock performance of +117.9%, which outperforms the peer group median by +105.3 percentage points — well above the 50pp threshold needed to trigger a concern — and no overboarding, attendance, independence, or familial relationship issues apply.
Dr. Ferrari has served since 2010 with deep biotechnology and nanomedicine expertise, the company's 3-year TSR strongly outperforms peers, he meets all attendance and independence requirements, and he serves on no external public company boards creating overboarding concerns.
Dr. Lu joined the board in 2024 (within the past 24 months), making her exempt from the TSR trigger under policy; she holds two outside public board seats (Terns Pharmaceuticals, Zenas Biopharma), which is below the four-seat overboarding threshold, and she brings strong biotech investment and capital markets expertise.
Dr. Olukotun has served since 2020 with extensive biopharma clinical development experience, the company's 3-year TSR strongly outperforms peers, he holds one outside public board seat (Tonix Pharmaceuticals) well below the overboarding threshold, and all attendance and independence criteria are met.
Dr. Perry has served since 2011 with extensive biopharma executive and board experience, the company's 3-year TSR strongly outperforms peers, he holds no current outside public company board seats, and all attendance and independence criteria are met.
Ms. Vakiener joined the board in 2022 with strong commercial biopharma experience, the company's 3-year TSR strongly outperforms peers, she holds no current outside public company board seats (her prior Chimerix seat ended with its acquisition in April 2025), and all attendance and independence criteria are met.
Mr. Waddill has served since 2018 as Lead Independent Director and Audit Committee Chair, bringing certified public accounting and biotech CFO experience; he holds two outside public board seats (Protagonist Therapeutics, Annexon) below the overboarding threshold, the company's 3-year TSR strongly outperforms peers, and all attendance and independence criteria are met.
All seven director nominees receive a FOR recommendation. The company's 3-year price return of +117.9% outperforms the peer group median by +105.3 percentage points, far exceeding the +50pp threshold that would need to be breached to trigger TSR-based concerns under policy. Hongbo Lu, who joined in 2024, is additionally exempt from the TSR trigger as a director within 24 months of joining. No overboarding, attendance, independence, familial relationship, or qualification concerns are identified for any nominee.
Say on Pay
✓ FORCEO
Christopher Anzalone
Total Comp
$9,029,861
Prior Support
91%%
The prior year Say on Pay vote received 91% support, well above the 70% threshold that would require a response, and the compensation committee made no adverse changes. CEO total compensation of approximately $9.0 million is reasonable for a biotech CEO at an $8 billion market cap company, and the pay structure is well-designed: roughly 70% of the CEO's long-term equity is in performance stock awards tied to specific clinical and regulatory milestones (such as FDA submissions and Phase 2 trial initiations), with only about 30% in time-based restricted stock — well above the 50-60% variable pay threshold required by policy. The company's 3-year stock return of +117.9% dramatically outperforms the peer group median, confirming that above-benchmark incentive pay has been backed by genuine shareholder value creation.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
KPMG LLP is a Big 4 firm appropriate for a company of Arrowhead's size and complexity. The proxy filing text does not include a detailed fee breakdown table with specific dollar amounts in the extracted section, so the non-audit fee ratio trigger cannot be evaluated numerically; however, no fee data suggesting an independence concern is available, KPMG's tenure is not disclosed in the available text so the tenure trigger does not fire under policy (which requires confirmed data), and no material financial restatements are disclosed. The default FOR vote applies.
Overall Assessment
Arrowhead's 2026 annual meeting ballot is straightforward and shareholder-friendly across all standard proposals: the director slate is clean with no TSR, overboarding, or independence concerns, supported by exceptional 3-year stock outperformance of +105 percentage points above the peer median; the CEO compensation program is well-structured with strong performance-link and high prior-year shareholder approval; and the auditor ratification presents no apparent independence or quality concerns. The only item outside current policy coverage is the equity plan amendment, which shareholders should evaluate independently based on the dilution and governance details noted above.
Compensation Peer Group
20 companies disclosed in 2026 proxy filing